These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 10809213

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
    DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares CF, DeNardo SJ.
    Clin Cancer Res; 1999 Mar; 5(3):533-41. PubMed ID: 10100704
    [Abstract] [Full Text] [Related]

  • 3. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL, DeNardo SJ, Shen S, DeNardo DA, Mirick GR, Macey DJ, Lamborn KR.
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [Abstract] [Full Text] [Related]

  • 4. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
    DeNardo SJ, DeNardo GL, Kukis DL, Shen S, Kroger LA, DeNardo DA, Goldstein DS, Mirick GR, Salako Q, Mausner LF, Srivastava SC, Meares CF.
    J Nucl Med; 1999 Feb; 40(2):302-10. PubMed ID: 10025839
    [Abstract] [Full Text] [Related]

  • 5. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    O'Donnell RT, Shen S, Denardo SJ, Wun T, Kukis DL, Goldstein DS, Denardo GL.
    Anticancer Res; 2000 Feb; 20(5C):3647-55. PubMed ID: 11268433
    [Abstract] [Full Text] [Related]

  • 6. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
    O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Mirick GR, DeNardo SJ.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3330s-3336s. PubMed ID: 10541382
    [Abstract] [Full Text] [Related]

  • 7. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
    DeNardo GL, DeNardo SJ, O'Donnell RT, Kroger LA, Kukis DL, Meares CF, Goldstein DS, Shen S.
    Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
    [Abstract] [Full Text] [Related]

  • 8. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
    O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Carr CE, Mirick GR, DeNardo SJ.
    J Nucl Med; 1999 Dec; 40(12):2014-20. PubMed ID: 10616879
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, Swayne LC, Alavi A, Goldenberg DM.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [Abstract] [Full Text] [Related]

  • 10. Metabolite production in patients with lymphoma after radiometal-labeled antibody administration.
    DeNardo GL, DeNardo SJ, Kukis DL, O'Donnell RT, Shen S, Mirick GR, Meares CF.
    J Nucl Med; 2001 Sep; 42(9):1324-33. PubMed ID: 11535720
    [Abstract] [Full Text] [Related]

  • 11. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
    Denardo GL, Denardo SJ, Kukis DL, O'Donnell RT, Shen S, Goldstein DS, Kroger LA, Salako Q, Denardo DA, Mirick GR, Mausner LF, Srivastava SC, Meares CF.
    Anticancer Res; 1998 Sep; 18(4B):2779-88. PubMed ID: 9713461
    [Abstract] [Full Text] [Related]

  • 12. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
    O'Donnell RT, DeNardo SJ, Miers LA, Kukis DL, Mirick GR, Kroger LA, DeNardo GL.
    Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
    [Abstract] [Full Text] [Related]

  • 13. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
    Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM.
    J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
    [Abstract] [Full Text] [Related]

  • 14. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, Ohlsson T, Stenberg L, Strand SE, Tennvall J.
    Clin Cancer Res; 2005 Jul 15; 11(14):5215-22. PubMed ID: 16033839
    [Abstract] [Full Text] [Related]

  • 15. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
    Richman CM, DeNardo SJ, O'Donnell RT, Goldstein DS, Shen S, Kukis DL, Kroger LA, Yuan A, Boniface GR, Griffith IJ, DeNardo GL.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3243s-3248s. PubMed ID: 10541370
    [Abstract] [Full Text] [Related]

  • 16. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA.
    J Nucl Med; 2003 Mar 15; 44(3):465-74. PubMed ID: 12621016
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
    Carrasquillo JA, White JD, Paik CH, Raubitschek A, Le N, Rotman M, Brechbiel MW, Gansow OA, Top LE, Perentesis P, Reynolds JC, Nelson DL, Waldmann TA.
    J Nucl Med; 1999 Feb 15; 40(2):268-76. PubMed ID: 10025834
    [Abstract] [Full Text] [Related]

  • 19. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF.
    J Nucl Med; 2005 Apr 15; 46(4):642-51. PubMed ID: 15809487
    [Abstract] [Full Text] [Related]

  • 20. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM.
    J Nucl Med; 2003 Dec 15; 44(12):2000-18. PubMed ID: 14660727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.